Center for Genetic Engineering and Biotechnology 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases   2 Products   0 Trials   108 News 


12»
  • ||||||||||  CIGB-300 / Center for Genetic Engineering and Biotechnology
    Journal:  Time- and dose-dependent effects of CIGB-300 on the proteome of lung squamous cell carcinoma. (Pubmed Central) -  Jul 15, 2025   
    Likewise, we observed a consistent downregulation of different proteins that had been already reported to be inhibited by CIGB-300 in lung adenocarcinoma and acute myeloid leukemia. Overall, our proteomics-guided strategy based on time and drug dose served to uncover novel clues supporting the CIGB-300 cytotoxic effect and also to identify putative pharmacodynamic biomarkers in NSCLC.
  • ||||||||||  Abdala (CIGB-66) / Center for Genetic Engineering and Biotechnology, Mambisa (CIGB-669) / Center for Genetic Engineering and Biotechnology
    Journal:  Validation and Clinical Performance of a Non-Commercial ELISA for SARS-CoV-2 Anti-RBD IgA Antibodies. (Pubmed Central) -  Feb 15, 2025   
    This assay was found to be highly accurate and reproducible for the quantification of anti-RBD IgA, met the most stringent acceptance criteria and is fit for purpose. It is currently being used to evaluate the immunogenicity of the Abdala and Mambisa vaccines.
  • ||||||||||  Abdala (CIGB-66) / Center for Genetic Engineering and Biotechnology
    Predicting the Etiology of Hearing Loss With a Joint (Reflection-Distortion) OAE Profile (Peninsula Ballroom) -  Feb 5, 2025 - Abstract #ARO2025ARO_138;    
    Exploiting these differences (which likely reflect distinct generation mechanisms), appears to enhance the differential diagnosis of hearing loss, although it is likely that accuracy here was limited by our relatively small cohort. Using the Joint-OAE Profile in differential diagnosis of hearing loss warrants further development.
  • ||||||||||  Undisclosed HBV therapeutic / Shanghai Jinwei Biotechnology, TheraVectys, HeberNasvac (ABX203) / Center for Genetic Engineering and Biotechnology, Abivax
    Review, Journal:  HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. (Pubmed Central) -  Jan 13, 2025   
    Aguilar JC, Akbar SMF, Al-Mahtab M, et al. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2024;14(2):221-237.
  • ||||||||||  Abdala (CIGB-66) / Center for Genetic Engineering and Biotechnology
    Journal:  Grafting glycoprotein-derived oligosaccharides structures onto non-glycosylated polypeptides. (Pubmed Central) -  Nov 17, 2024   
    It consists on the digestion of the protein, followed by selective capture of the oligosaccharides bound to di-/tripeptides, and their grafting onto a non-glycosylated receptor protein by chemical crosslinking. Glycopeptides derived from C-RBD-H6 PP protein, the active ingredient of the Abdala vaccine were efficiently grafted onto a non-glycosylated protein as evidenced by western blotting.
  • ||||||||||  silmitasertib (CX-4945) / Senhwa Biosci, University of California, CIGB-300 / Center for Genetic Engineering and Biotechnology
    Journal:  "Phosphoproteomic quantification based on phosphopeptide intensity or occupancy? An evaluation based on casein kinase 2 downstream effects". (Pubmed Central) -  Sep 8, 2024   
    A low overlap between the phosphoproteomes quantified by intensity and occupancy was obtained illustrating that new developments in proteomics techniques are needed to improve the performance of the occupancy approach. Even in such context, results indicate that occupancy quantification performs better than phosphorylation quantification based on intensity reinforcing the importance of such quantification approach to describe phosphoproteomic data.
  • ||||||||||  Journal:  Comparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines. (Pubmed Central) -  Mar 28, 2024   
    The vaccines under comparison include well-known ones like Pfizer (BNT162b2) and AstraZeneca (ChAdOx1-S), alongside less-studied vaccines including Soberana (Soberana 02), Abdala (CIGB-66), and Sputnik V/Sputnik Light...Overall, we found no evidence of waning in the antibody magnitude across vaccines. Our study supports the conclusion that populations with high infection rates still benefit substantially from vaccination.
  • ||||||||||  HeberNasvac (ABX203) / Center for Genetic Engineering and Biotechnology, Abivax
    Journal, IO biomarker:  Preparing for the Next Pandemic: Increased Expression of Interferon-Stimulated Genes After Local Administration of Nasalferon or HeberNasvac. (Pubmed Central) -  Dec 20, 2023   
    In most cases, the gene expression induced by HeberNasvac was similar in profile and intensity to the expression induced by Nasalferon and significantly superior to that observed in untreated controls. The immune stimulatory effect of HeberNasvac on ISGs paved the way for its future use as an innate immunity stimulator in elderly persons and immunocompromised subjects or as part of Mambisa, a nasal vaccine to prevent severe acute respiratory syndrome coronavirus 2 infection.
  • ||||||||||  Abdala (CIGB-66) / Center for Genetic Engineering and Biotechnology
    Journal:  On the dentition, tooth replacement, and taxonomic status of Charruodon tetracuspidatus Abdala & Ribeiro, (Pubmed Central) -  Nov 11, 2023   
    Additionally, the specimen could potentially be an ontogenetically immature form of another taxon, or a yet unknown species of probainognathian cynodont. Therefore, Charruodon tetracuspidatus is here designated as a nomen dubium, given the challenges of maintaining the species as valid.
  • ||||||||||  Jusvinza (CIGB-258) / Center for Genetic Engineering and Biotechnology
    Journal:  Alginate Microsponges as a Scaffold for Delivery of a Therapeutic Peptide against Rheumatoid Arthritis. (Pubmed Central) -  Oct 14, 2023   
    Alginate microsponges showed 80% loading capacity and sustained peptide release over a few hours through a diffusional mechanism favored by partial erosion of the polymer scaffold. The edible and biocompatible nature of alginate polymers open promising perspectives for developing a new generation of polysaccharide-based carriers for the controlled delivery of peptide drugs, exploiting alternative routes with respect to intravenous administration.
  • ||||||||||  HEBERSaVax (CIGB-247) / Center for Genetic Engineering and Biotechnology, Heber Biotec
    Modulating tumor microenvironment using a VEGF active immunotherapeutic approach in gastrointestinal tumors: Beyond angiogenesis modulation () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_1644;    
    Conclusions CIGB-247 antigen-based vaccine increased tumor-infiltrating lymphocytes and reversed the immunosuppressive effect of the tumor microenvironment in the CT26 mouse model. Such results were corroborated in a GIC patient cohort indicating that the strategy might be a successful treatment option for such patients by modifying systemic and tumor microenvironment beyond angiogenesis modulation.
  • ||||||||||  HeberNasvac (ABX203) / Center for Genetic Engineering and Biotechnology, Abivax
    Review, Journal:  Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B. (Pubmed Central) -  Dec 24, 2022   
    Aimed at understanding the clinical results of Nasvac and other therapeutic vaccines under development, we discuss the rationale of administering a therapeutic vaccine through the nasal route and also the current alternatives to combine therapeutic vaccines and antivirals (NUCs). We also disclose potential applications of this product in novel fields of immunotherapy.
  • ||||||||||  Abdala (CIGB-66) / Center for Genetic Engineering and Biotechnology
    Journal:  Demographic changes in an Atlantic Forest primate community following a yellow fever outbreak. (Pubmed Central) -  Sep 10, 2022   
    We investigated demographic changes in three primate species (Alouatta guariba, Sapajus nigritus, and Callithrix flaviceps) at the Reserva Particular do Patrimônio Natural-Feliciano Miguel Abdala, Caratinga, Minas Gerais, Brazil, following a yellow fever outbreak (YFO) by comparing their population sizes before (2015) and after the outbreak (2017-2018), and by monitoring the size, composition, and reproductive status of groups from 2017 to 2021...The female-biased adult sex ratio and presence of infants and juveniles in the A. guariba and S. nigritus groups are encouraging signs, but there is still great concern, especially for C. flaviceps. Continued monitoring of the demographics of these primates is needed as their persistence appears to still be at risk.
  • ||||||||||  HEBERSaVax (CIGB-247) / Center for Genetic Engineering and Biotechnology, Heber Biotec, Avastin (bevacizumab) / Roche
    Journal:  Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF. (Pubmed Central) -  Aug 26, 2022   
    The production of systemic IgG antibodies and the presence of VEGF in another compartment, almost exclusively within platelets, have arisen some questions about this effect detected in the vaccinated-cancer patients. Based on some relevant published works about platelet endocytosis and VEGF pharmacodynamics during bevacizumab treatment as well as the phase I clinical data of CIGB-247, this investigation aims to hypothesize and analyze the potential mechanisms involved in the reduction of platelet-derived free VEGF as a result of vaccination with CIGB-247.Abbreviations: FcγR: Fc gamma receptors; IC: immune complexes; VEGF: vascular endothelial growth factor; VEGFR1: vascular endothelial growth factor receptor 1; VEGFR2: vascular endothelial growth factor receptor 2.
  • ||||||||||  CIGB-300 / Center for Genetic Engineering and Biotechnology
    Journal:  CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition. (Pubmed Central) -  Apr 2, 2022   
    Thus, oxidative stress might play a relevant role on CIGB-300-induced apoptosis in HL-60 but not in OCI-AML3 cells. Importantly, these findings provide first-hand insights concerning the CIGB-300 antileukemic effect and draw attention to the existence of both common and tailored response patterns triggered by CK2 inhibition in different AML backgrounds, a phenomenon of particular relevance with regard to the pharmacologic blockade of CK2 and personalized medicine.
  • ||||||||||  HeberNasvac (ABX203) / Center for Genetic Engineering and Biotechnology, Abivax
    Limited value of HBV-RNA levels for the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in HBe antigen negative chronic hepatitis B patients (Poster Area) -  Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_958;    
    P2b
    Serum level of HBV-RNA, HBsAg and HBcrAg were determined in 154 HBeAg negative patients, participating in a prospective, multicenter therapeutic vaccination trial (ABX-203, NCT02249988) or in an observational register trial (Terminator 2), before stop of NA therapy...Two thirds of patients were treated with entecavir (n = 94/154; 61%), while the rest received tenofovir... In a cohort of exclusively HBeAg negative patients no improvement in relapse predictionwas achieved by considering HBVRNA BL levels.
  • ||||||||||  HeberNasvac (ABX203) / Center for Genetic Engineering and Biotechnology, Abivax
    Journal:  Innate Immune Stimulation Should not be Overlooked in Post-exposure Prophylaxis and Early Therapy for Coronavirus Infections. (Pubmed Central) -  Feb 22, 2022   
    This nasal formulation of hepatitis B vaccine has demonstrated its capacity to stimulate innate immunity markers (TLR3, TLR7 and TLR8 in tonsils) at the virus' entry site, in systemic compartments (HLA class II in monocytes and lymphocytes) and in the activation of dendritic cells, lymphocytes and other cell lines in vitro and ex vivo. In addition, research generated by the current pandemic may obtain results useful for treating other acute respiratory infections, which have long been main drivers of mortality among older adults and in early childhood.
  • ||||||||||  HeberNasvac (ABX203) / Center for Genetic Engineering and Biotechnology, Abivax
    Journal:  Cuban Prophylactic and Therapeutic Vaccines for Controlling Hepatitis B. (Pubmed Central) -  Nov 10, 2021   
    This precursor vaccine, which combines Heberbiovac HB with a recombinant antigen from the virus nucleocapsid (rHBcAg), was patented and licensed in 2015 by the Cuban regulatory authority. This article provides an overview of the progress-to-date on the development of this therapeutic vaccine, including clinical trials (some completed and others ongoing) to determine safety, efficacy and therapeutic benefits.
  • ||||||||||  CIGB-300 / Center for Genetic Engineering and Biotechnology
    Journal:  Tuning the Anti-Angiogenic Effect of the P15 Peptide Using Cyclic Trypsin Inhibitor Scaffolds. (Pubmed Central) -  Aug 26, 2021   
    A novel proapoptotic peptide, CIGB-300 (P15-Tat), has been shown to be involved in the casein kinase II phosphorylation pathway, conferring it with antiangiogenic activity...Overall, the results show the value of P15 being engineered into cyclic trypsin inhibitor scaffolds for improving antiangiogenic activity and stability. More broadly, the study highlights the versatility of cyclic peptide frameworks in drug design for antiangiogenic therapies.
  • ||||||||||  CIGB-300 / Center for Genetic Engineering and Biotechnology
    Clinical, Journal:  Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. (Pubmed Central) -  Aug 7, 2021   
    However, in vivo pull-down experiments and phosphoproteomic analysis evidenced that CIGB-300 targeted the CK2α catalytic subunit, different ribosomal proteins, and inhibited the phosphorylation of a common CK2 substrates array among both AML backgrounds. Remarkably, our results not only provide cellular and molecular insights unveiling the complexity of the CIGB-300 anti-leukemic effect in AML cells but also reinforce the rationale behind the pharmacologic blockade of protein kinase CK2 for AML-targeted therapy.